Financial Performance - The company's operating revenue for Q1 2025 was ¥91,423,973.13, representing an increase of 11.75% compared to ¥81,812,580.71 in the same period last year[4]. - The net profit attributable to shareholders was ¥1,504,070.84, a significant recovery from a loss of ¥36,471,708.61 in the previous year[4]. - The net cash flow from operating activities improved to ¥9,694,526.65, up from a negative cash flow of ¥53,262,841.06 in the same period last year[4]. - The basic and diluted earnings per share improved to ¥0.003, recovering from a loss of ¥0.084 per share in the same period last year[4]. - Total operating revenue for Q1 2025 reached ¥91,423,973.13, an increase of 11.6% compared to ¥81,812,580.71 in Q1 2024[28]. - Net profit for Q1 2025 was ¥1,398,207.37, a significant recovery from a net loss of ¥36,640,808.15 in Q1 2024[29]. - Total comprehensive income for Q1 2025 was ¥1,794,476.63, contrasting with a total comprehensive loss of ¥38,293,841.23 in Q1 2024[29]. Research and Development - Research and development expenses totaled ¥73,584,391.53, an increase of 11.25% from ¥66,140,705.16, accounting for 80.49% of operating revenue[5]. - The company is focusing on high-quality growth and increasing R&D investment to support technological innovation[12]. - R&D expenses rose to ¥69,354,841.80, representing an increase of 9.0% from ¥63,091,569.46 in the same period last year[28]. - Research and development expenses increased to CNY 51,535,716.25 in Q1 2025, compared to CNY 44,626,845.94 in Q1 2024, reflecting a growth of approximately 15.4%[40]. Assets and Liabilities - Total assets decreased by 1.50% to ¥2,428,636,748.94 from ¥2,465,703,479.40 at the end of the previous year[5]. - As of March 31, 2025, the total assets amounted to RMB 2,428,636,748.94, while total liabilities were RMB 448,187,131.23[24]. - The company's total assets decreased from CNY 2,708,159,701.69 as of December 31, 2024, to CNY 2,688,528,529.52 as of March 31, 2025, representing a decline of approximately 0.73%[36]. - The company's total liabilities decreased from CNY 555,245,640.01 as of December 31, 2024, to CNY 522,787,740.82 as of March 31, 2025, indicating a decline of approximately 5.83%[38]. - The total current liabilities decreased from CNY 435,466,595.31 as of December 31, 2024, to CNY 413,857,477.78 as of March 31, 2025, a reduction of approximately 4.93%[38]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,350[9]. - The board of directors underwent changes, with Zhang Wei elected as an independent director[16]. - The company has not engaged in any share lending or borrowing activities among the top shareholders[11]. - The company approved a share repurchase plan, intending to buy back shares at a price not exceeding RMB 30 per share, with a total fund of no less than RMB 20 million and no more than RMB 40 million[19]. - A total of 1,300,070 shares were repurchased, accounting for 0.30% of the total share capital, with an average repurchase price of RMB 15.39 per share, totaling RMB 20,007,759.10[19]. - The company completed the first vesting period of the 2023 restricted stock incentive plan, with 126,900 shares listed for circulation, increasing the total share capital to 433,931,345 shares[21]. Market and Competitive Position - The company continues to focus on enhancing its market competitiveness through technological development solutions, which have shown rapid growth[7]. - The company plans to expand its product market and enhance its core competitiveness in the industry[12]. - Domestic revenue accounted for 76.24% of the main business income, totaling 69.52 million RMB, while international revenue made up 23.76%, amounting to 21.67 million RMB[15]. - EDA software licensing generated 69.36 million RMB, constituting 76.07% of the main business revenue[15]. - The semiconductor device characteristic testing system business generated 8.06 million RMB, representing 8.84% of the main business revenue[15]. Cash Flow and Investment Activities - The company experienced a net cash outflow from investing activities of ¥4,042,070.15 in Q1 2025, compared to a larger outflow of ¥22,983,479.73 in Q1 2024[33]. - The company reported cash outflows from operating activities of $122,548,459.22 in Q1 2025, up from $71,900,850.09 in Q1 2024, indicating a 70% increase in operational expenses[44]. - The company received $2,193,000,000.00 from investment recoveries in Q1 2025, indicating strong investment performance[44]. - The company reported a significant increase in fair value gains, with CNY 14,070,098.15 recognized in Q1 2025, compared to a loss of CNY 22,062,016.88 in Q1 2024[41].

四川天微电子股份有限公司 2024年度业绩快报暨业绩预告更正公告 证券代码：688511 证券简称：天微电子 公告编号：2025-015 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川天微电子股份有限公司（以下简称"公司"）于 2025 年 1 月 18 日和 2025 年 2 月 28 日在《上海证券报》《中国证券报》《证券日报》《证券时报》 及上海证券交易所网站（www.sse.com.cn）披露了公司《2024 年年度业绩预亏公 告》和《2024 年度业绩快报》，现对相关内容修正如下，财务数据未经会计师 事务所审计，具体以公司将来披露的 2024 年年度报告为准，提请投资者注意投 资风险。 | 项目 | 修正前 （业绩预 | 本报告期 | 修正后 | | 修正后 的增减 变动幅 | | --- | --- | --- | --- | --- | --- | | | | 修正前 | | 上年同期 | | | | | （业绩快报） | | | | | | 告） | | | | 度（％） | | 营业总收入 | 不适 ...

Financial Performance - The company reported a revenue of 77.76 million yuan for the year 2024, a decrease of 44.65% year-over-year[4]. - The net profit attributable to the parent company was -29.16 million yuan, representing a decline of 158.66% compared to the previous year[4]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was -34.83 million yuan, down 222.86% year-over-year[4]. - The decline in revenue was primarily due to decreased demand for the company's main product, the fire suppression and explosion suppression system, influenced by macroeconomic policies affecting the automotive industry[4]. - The company will not distribute cash dividends or issue bonus shares for the fiscal year 2024, considering its performance and future funding needs[9]. - The company reported a net profit attributable to the parent company of -29,157,332.80 RMB for the fiscal year 2024, with undistributed profits amounting to 146,779,422.64 RMB[178]. - The company plans no cash dividends, stock bonuses, or capital reserve transfers for the 2024 profit distribution[178]. Research and Development - The company increased its R&D investment, with R&D expenses accounting for 28.29% of revenue, up 16.87 percentage points from the previous year[26]. - The company applied for 13 new invention patents in 2024, with 2 patents granted, increasing its total to 21 active patents[38]. - The company is actively exploring the application of artificial intelligence in the security protection sector, focusing on multi-scenario applications[38]. - Research and development investment for the year was 21.997 million yuan, an increase of 37.12%, accounting for 28.29% of total revenue[40]. - The company has developed its fifth-generation fire extinguishing and explosion suppression system, achieving key performance indicators comparable to international products[77]. - The company continues to increase R&D investment in various projects, including general collection drive devices and UV optical detector technology[199]. Market and Product Development - The company is actively expanding its civilian product market, leveraging over 20 years of accumulated technology in real-time detection and intelligent control[42]. - A new AI-based electric vehicle safety protection system has been developed, featuring automatic fire alarm and extinguishing capabilities[43]. - The company is expanding into the civilian market, leveraging military technology for customized solutions in various sectors, but faces risks from macroeconomic factors[88]. - The company plans to expand its civil product market by leveraging over 20 years of accumulated core technologies, aiming to enhance competitiveness and influence in the civil market, particularly in the renewable energy sector[132]. - The company has established a comprehensive research and production technology platform for nuclear and biochemical protection systems, expanding its product applications across various military platforms[58]. Risks and Challenges - The company is at risk of delisting as it reported a negative net profit and revenue below 100 million yuan, which triggers delisting warnings under the Shanghai Stock Exchange rules[7]. - The company faces risks related to temporary price adjustments for military products, which could adversely impact revenue if significant reductions occur[5]. - The company anticipates a risk of further delays or changes in fundraising projects due to external uncertainties and has postponed the expected completion date to July 30, 2026[98]. - The company faces risks related to fluctuations in commissioned research project income, which is dependent on the number and scale of projects completed in a given period[87]. - The company is exposed to risks from potential reductions in national defense spending, which could impact military orders and profitability[95]. Governance and Management - The company has established a modern corporate governance structure, enhancing the operation mechanisms of the shareholders' meeting, board of directors, supervisory board, and management[188]. - The board of directors consists of 8 members, including 3 independent directors, ensuring compliance with legal requirements and effective decision-making[139]. - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making and operations, thereby safeguarding its autonomy[139]. - The company has proposed a three-year shareholder return plan for 2024-2026, reflecting a commitment to enhancing shareholder value[147]. - The company has appointed new independent directors, enhancing its governance structure and oversight capabilities[147]. Environmental and Social Responsibility - The company invested 3.41 million yuan in environmental protection during the reporting period[190]. - The company has achieved a 100% compliance rate in environmental management goals, ensuring zero accidents in safety and environmental protection[196]. - The company actively promotes ESG awareness among employees and integrates ESG work into its business philosophy[185]. - The company emphasizes data privacy protection and ensures compliance in product R&D and application[200].

Financial Performance - The company's operating revenue for Q1 2025 was ¥714,718,608.26, a decrease of 6.00% compared to ¥760,368,146.77 in the same period last year[4] - Net profit attributable to shareholders was ¥12,819,736.02, a significant turnaround from a loss of ¥187,855,150.85 in the previous year[4] - Basic and diluted earnings per share were both ¥0.08, compared to a loss of ¥1.53 per share in the previous year[4] - The company's operating profit improved to CNY 15.31 million from a loss of CNY 210.88 million year-over-year[20] - The net profit for Q1 2025 was a loss of ¥3,642,164.42, compared to a loss of ¥162,077,080.95 in Q1 2024, indicating a significant improvement in performance[32] - The total comprehensive loss for Q1 2025 was ¥14,977,117.44, compared to a loss of ¥162,253,464.31 in Q1 2024, showing a significant reduction in losses[33] Cash Flow - The net cash flow from operating activities was ¥118,446,241.16, recovering from a negative cash flow of ¥269,368,898.76 in the same period last year[4] - In Q1 2025, the net cash flow from operating activities was ¥118,446,241.16, a significant improvement compared to a net outflow of ¥269,368,898.76 in Q1 2024[25] - Total cash inflow from operating activities in Q1 2025 was ¥667,586,273.29, down 16.4% from ¥798,646,636.74 in Q1 2024[25] - Cash outflow from operating activities decreased to ¥549,140,032.13 in Q1 2025, compared to ¥1,068,015,535.50 in Q1 2024, representing a reduction of 48.6%[25] - The company reported a net cash outflow from investing activities of ¥113,600,745.35 in Q1 2025, compared to a smaller outflow of ¥48,145,808.15 in Q1 2024[35] - The company's financing activities resulted in a net cash outflow of ¥141,415,878.05 in Q1 2025, contrasting with a net inflow of ¥417,108,616.49 in Q1 2024[35] Assets and Liabilities - Total assets decreased by 4.33% to ¥8,412,380,380.31 from ¥8,793,513,269.67 at the end of the previous year[5] - Total assets decreased to CNY 8.41 billion from CNY 8.79 billion, a decline of 4.3%[17] - Total liabilities decreased to CNY 6.18 billion from CNY 6.52 billion, a reduction of 5.2%[17] - Current liabilities decreased to ¥5,387,105,096.64 as of March 31, 2025, from ¥6,021,555,571.06 as of December 31, 2024, indicating a reduction of 10.6%[30] Research and Development - Research and development expenses totaled ¥87,600,222.83, down 18.46% from ¥107,426,861.71, with R&D expenses accounting for 12.26% of operating revenue, a decrease of 1.87 percentage points[5] - The company reported a significant reduction in research and development expenses to CNY 87.60 million from CNY 107.43 million, a decrease of 18.5%[20] - Research and development expenses decreased to ¥51,622,531.61 in Q1 2025 from ¥75,144,432.15 in Q1 2024, a reduction of approximately 31.4%[32] Shareholder Information - As of March 31, 2025, the total number of common shareholders was 13,948[11] - The largest shareholder, Huizhou Liyuanheng Investment Co., Ltd., holds 56,381,965 shares, accounting for 33.42% of total shares[11] - The company repurchased a total of 1,194,624 shares, representing 0.71% of the total share capital, with a total expenditure of approximately RMB 33.49 million[14] - The company plans to use between RMB 30 million and RMB 40 million for share repurchase, with a maximum price of RMB 36.60 per share[13] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[12] Cost Management - The company implemented cost control measures that led to improved gross margins and reduced operating expenses, contributing to the turnaround in profitability[8] - Total operating costs decreased to CNY 692.53 million from CNY 938.93 million, representing a reduction of 26.2%[20] - Operating costs decreased to ¥618,323,716.91 in Q1 2025 from ¥677,874,381.87 in Q1 2024, reflecting a reduction of approximately 8.8%[32]

Financial Performance - The company reported a decline in revenue due to excess capacity in the downstream lithium battery market, leading to reduced or canceled equipment investment plans from some customers[5]. - In 2024, the company achieved total operating revenue of CNY 2,482,135,940.85, a decrease of 50.30% compared to the previous year[20]. - The net profit attributable to shareholders was CNY -1,044,132,434.11, compared to CNY -188,015,289.09 in the previous year, indicating a significant loss[23]. - The basic and diluted earnings per share for 2024 were both CNY -8.12, a decline from CNY -1.70 in the previous year[21]. - The company's gross margin for the reporting period was 7.77%, a decrease of 18.67 percentage points compared to the same period last year, primarily due to intensified competition in the power lithium battery sector[123]. - Operating costs decreased to CNY 2,289,151,804.73, down 37.68% year-on-year, primarily due to reduced revenue and adjustments in product structure[128]. - The company's financial expenses have increased due to expanded bank borrowings and bill discounts, adding to the operational burden[5]. - The company reported a significant operating loss during the reporting period, but operational quality is showing signs of recovery, with a 24.85% reduction in total expenses compared to the previous year[34]. Cash Flow and Investments - The company's net cash flow from operating activities turned positive at CNY 68,723,951.58, compared to a negative CNY -1,263,691,185.67 in the previous year[24]. - The company has implemented stricter cash collection policies and improved communication with customers, contributing to better cash flow management[148]. - The cash flow from investment activities improved to CNY 18,279,029.16, compared to a negative cash flow of CNY 387,396,639.40 in the previous year[129]. - The company reported a net cash outflow from financing activities of CNY 2,242,713.95, a 100.33% decrease compared to the previous year[129]. - The company has achieved a significant reduction in capitalized R&D investment, which is now at 0, down from ¥12.48 million last year[99]. Research and Development - Research and development expenses accounted for 13.55% of operating revenue, an increase of 2.94 percentage points from the previous year[22]. - The total R&D investment for the year is approximately ¥336.41 million, a decrease of 36.51% compared to the previous year, with a ratio of R&D investment to revenue increasing by 2.94 percentage points to 13.55%[99]. - The company is investing heavily in R&D, with a budget increase of 30% to enhance technology development and innovation[180]. - The company has registered 525 software copyrights, with 39 new registrations during the reporting period[96]. - The company has applied for a total of 3,456 patents, with 2,415 patents granted as of December 31, 2024, including 247 new patents granted during the reporting period[96]. Market and Competitive Landscape - The decline in revenue was attributed to intensified competition in the new energy sector and a strategic decision to reduce low-margin orders[23]. - The company is a leading player in the global lithium battery manufacturing equipment industry, focusing on high-end intelligent manufacturing equipment[40]. - The new energy vehicle market is expected to maintain high growth momentum due to expanded support for vehicle scrapping and replacement policies[68]. - The company is actively pursuing market expansion in the financial sector through smart construction projects with state-owned banks[37]. - The company is expanding its market presence by providing tailored solutions across multiple sectors, including renewable energy and automotive industries, to meet growing demand[48]. Technology and Innovation - The company has made significant advancements in AI computing and smart manufacturing, winning contracts for new factory projects in the logistics and warehousing sectors[34]. - The company emphasizes research and development focused on intelligent manufacturing technologies tailored to downstream industry needs, ensuring alignment with market demands and strategic goals[53]. - The company has developed advanced battery detection technologies, including high-pressure direct current temperature control, achieving temperature control accuracy within ±2°C[85]. - The introduction of digital and intelligent technologies into equipment has improved detection efficiency and automation levels[84]. - The company is focusing on the development of intelligent edge computing units to optimize control models and enhance the stability and safety of the assembly process[85]. Corporate Governance and Compliance - The company has received a standard unqualified audit opinion from Ernst & Young Hua Ming[6]. - The company has received multiple awards for its governance practices from the China Listed Companies Association[38]. - The company will implement a "value management system" to enhance corporate governance and transparency, aiming to improve overall company quality[170]. - The company plans to hold 5 shareholder meetings during the reporting period, ensuring compliance with legal requirements and protecting minority shareholder rights[172]. - The company maintains independence from its controlling shareholder in operations, assets, and finances, ensuring no interference in decision-making[174]. Future Outlook and Strategic Initiatives - The company plans to focus on core business development and improve operational quality, aiming for profitability by leveraging national support policies and industry recovery trends[167]. - The company intends to expand its overseas market presence, particularly in Southeast Asia, based on successful projects in Europe and the Americas[168]. - The company is considering strategic acquisitions to bolster its market position, with a target of acquiring two smaller firms by mid-2024[180]. - The company is committed to innovation in key technologies, including optical, mechanical, electrical, and software disciplines, to support rapid equipment iteration[168]. - The company is focusing on sustainability initiatives, aiming to reduce carbon emissions by 20% by 2025[181].

Financial Performance - The company reported a profit distribution plan for 2024, which includes no cash dividends, no bonus shares, and no capital reserve conversion into shares [8]. - The company has not achieved profitability since its listing, indicating ongoing investment in growth and development [6]. - In 2024, the company's operating revenue was CNY 274,850,777.34, a decrease of 42.77% compared to CNY 480,220,256.00 in 2023 [24]. - The net profit attributable to shareholders was a loss of CNY 19,981,182.92 in 2024, down 120.02% from a profit of CNY 99,828,173.71 in 2023 [24]. - The net cash flow from operating activities decreased by 49.00% to CNY 56,563,516.68 in 2024, compared to CNY 110,908,655.20 in 2023 [27]. - The company's total assets at the end of 2024 were CNY 1,053,411,101.81, down 8.39% from CNY 1,149,858,761.63 at the end of 2023 [24]. - The company reported a decrease in net assets attributable to shareholders by 9.37% to CNY 810,050,019.65 at the end of 2024 [24]. - The company faced increased competition and reduced customer investment willingness, impacting revenue negatively [26]. - The company’s revenue decreased due to fluctuations in downstream market demand and increased competition, leading to a decline in operating income [141]. Research and Development - Research and development expenses accounted for 14.70% of operating revenue in 2024, an increase of 7.79 percentage points from 6.91% in 2023 [25]. - The total R&D investment for the year reached ¥40,411,899.21, an increase of 21.81% compared to the previous year [111]. - The company submitted 146 new patent applications during the reporting period, including 21 invention patent applications [39]. - The company has received multiple accolades for its products, including recognition as the first domestic product in various categories from 2017 to 2024, highlighting its innovation and industry leadership [70]. - The company has established a comprehensive R&D system across eight major modules, enhancing its innovation and talent development efforts [124]. - The company has developed numerous core technologies in automated production, including high-speed multi-channel feeding technology and medical soft catheter shaping technology, which are leading in the domestic market [123]. - The company is actively engaged in the research and development of GLP-1 drugs to capitalize on the growing market [103]. Operational Risks and Compliance - The company faces potential operational risks, which are detailed in the report, emphasizing the need for investor caution [6]. - The audit report from Tianjian Accounting Firm confirmed a standard unqualified opinion, ensuring the accuracy of the financial statements [7]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties, ensuring financial integrity [10]. - The company has not violated decision-making procedures for external guarantees, maintaining compliance with regulations [10]. - The company has established a comprehensive internal control system and governance mechanism to improve risk management and ensure compliance with legal regulations [40]. Market Trends and Industry Insights - The domestic medical consumables industry is experiencing continuous growth, driven by factors such as an aging population and increasing healthcare expenditures, with a projected steady growth trend [65]. - The intelligent manufacturing equipment industry in China is benefiting from strong government support and the integration of new information technologies, leading to rapid market growth and expansion opportunities [64]. - The demand for intelligent production equipment in the medical consumables sector is increasing due to stricter government regulations and rising labor costs, creating a favorable market environment for intelligent equipment manufacturers [66]. - The medical device market is experiencing a slowdown in growth, with investment amounts declining year-on-year [142]. Strategic Initiatives and Future Plans - The company has outlined its future plans and development strategies, which are subject to investment risks and do not constitute a commitment to investors [9]. - The company plans to invest in the "Annual Production of 35 Units of Medical Equipment Intelligent Equipment Expansion Project" to enhance production efficiency and supply capacity, utilizing part of the raised funds for this initiative [190]. - The company aims to become a global leader in medical consumables automation, focusing on enhancing technology levels and developing intelligent equipment to improve assembly efficiency and product quality for downstream manufacturers [188]. - The company intends to expand its market presence in Europe, the Americas, and developing countries, aiming to increase product market penetration and share [194]. Investor Relations and Governance - The company actively engages in investor relations to enhance communication and improve its image in the capital market [40]. - The company will strengthen investor relations management to protect minority shareholders' rights and ensure compliance with relevant laws and regulations [196]. - The company plans to optimize organizational management to enhance operational efficiency and competitiveness through improved governance structures and decision-making mechanisms [198].

Financial Performance - The company's revenue for Q1 2025 was CNY 474,310,296.66, representing a 6.97% increase compared to CNY 443,405,252.67 in the same period last year[3]. - Net profit attributable to shareholders decreased by 61.60% to CNY 29,448,437.25 from CNY 76,687,049.55 year-over-year[3]. - Basic and diluted earnings per share decreased by 66.67% to CNY 0.02 from CNY 0.06 in the previous year[3]. - Total operating revenue for Q1 2025 reached ¥474,310,296.66, an increase from ¥443,405,252.67 in Q1 2024, representing a growth of approximately 6.4%[16]. - Net profit for Q1 2025 was ¥29,448,437.25, a decrease from ¥76,687,049.55 in Q1 2024, reflecting a decline of approximately 61.5%[18]. - Earnings per share for Q1 2025 were ¥0.02, down from ¥0.06 in Q1 2024, showing a reduction of 66.7%[18]. Cash Flow - The net cash flow from operating activities fell by 46.72% to CNY 74,234,875.87, primarily due to increased cash payments for goods and services[3]. - Cash inflow from operating activities totaled $587,060,291.56, an increase from $567,931,452.87 in the previous period, reflecting a growth of approximately 2.0%[20]. - Cash outflow from operating activities was $512,825,415.69, compared to $428,605,573.13 previously, indicating an increase of about 19.7%[20]. - Net cash flow from operating activities decreased to $74,234,875.87 from $139,325,879.74, representing a decline of approximately 46.6%[20]. - Cash inflow from investment activities was $2,517,759,615.21, significantly up from $430,357,193.97, marking an increase of around 485.5%[20]. - Cash outflow from investment activities rose to $2,522,894,583.03 from $665,098,796.56, reflecting an increase of about 278.5%[20]. - The net cash flow from investment activities was -$5,134,967.82, an improvement from -$234,741,602.59 in the previous period[21]. - Cash inflow from financing activities was $41,275,200.00, compared to no inflow in the previous period[21]. - Cash outflow from financing activities decreased to $67,743,716.58 from $244,758,183.85, a reduction of approximately 72.3%[21]. - The net cash flow from financing activities was -$67,743,716.58, improving from -$203,482,983.85 previously[21]. - The ending cash and cash equivalents balance was $988,482,353.22, up from $1,826,573,159.78 at the beginning of the period[21]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,921,485,746.87, a slight decrease of 0.99% from CNY 6,991,013,658.68 at the end of the previous year[4]. - Current assets decreased to CNY 2,190,362,208.87 from CNY 2,355,381,006.67, indicating a decline of approximately 7.0%[12]. - Cash and cash equivalents increased to CNY 988,482,353.22 from CNY 984,490,583.43, showing a growth of about 0.2%[12]. - The company's inventory rose to CNY 507,551,173.41 from CNY 468,474,132.37, reflecting an increase of approximately 8.4%[12]. - Short-term borrowings decreased significantly to CNY 94,614,827.96 from CNY 135,963,108.63, a reduction of about 30.4%[13]. - Total current liabilities decreased to CNY 643,825,685.08 from CNY 712,792,356.26, representing a decline of approximately 9.7%[13]. - Total liabilities decreased to ¥873,295,337.32 in Q1 2025 from ¥987,721,636.48 in Q1 2024, a reduction of about 11.6%[14]. - Total equity attributable to shareholders increased to ¥6,048,190,409.55 in Q1 2025 from ¥6,003,292,022.20 in Q1 2024, reflecting a growth of approximately 0.75%[14]. Research and Development - Research and development expenses totaled CNY 43,374,981.57, a 40.77% increase from CNY 30,812,790.94, accounting for 9.14% of revenue[3][4]. - Research and development expenses for Q1 2025 were ¥43,374,981.57, compared to ¥30,812,790.94 in Q1 2024, marking an increase of about 40.6%[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,752[7]. - The company has a major shareholder, Hefei Qizhong Technology Holding Co., Ltd., holding 33.40% of shares[8]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder holding over 33%[8]. Other Financial Metrics - The weighted average return on equity dropped by 0.82 percentage points to 0.49% from 1.31%[3]. - The company reported non-recurring gains and losses totaling CNY 465,771.35, with a significant portion attributed to asset disposal losses[5][6]. - The decline in net profit was mainly due to increased costs related to equipment depreciation, stock incentives, and labor expenses[6]. - The company reported a significant decrease in employee compensation liabilities, dropping to CNY 29,001,600.41 from CNY 70,641,541.97, a decline of approximately 58.9%[13].

Financial Performance - Revenue for Q1 2025 was CNY 190,809,757.15, a decrease of 55.39% compared to CNY 427,748,061.08 in the same period last year[5] - Net profit attributable to shareholders was CNY 28,879,698.84, down 27.68% from CNY 39,930,858.95 year-on-year[5] - Net profit after deducting non-recurring gains and losses decreased by 40.24%, amounting to CNY 21,462,613.84 compared to CNY 35,912,605.80 in the previous year[5] - Basic and diluted earnings per share were both CNY 0.18, representing a decrease of 30.77% from CNY 0.26[5] - Total operating revenue for Q1 2025 was ¥190.81 million, a decrease of 55.32% compared to ¥427.75 million in Q1 2024[20] - Net profit for Q1 2025 was ¥22.39 million, a decline of 43.58% from ¥39.68 million in Q1 2024[21] - Operating profit for Q1 2025 was ¥25.25 million, a decrease of 57.24% compared to ¥59.00 million in Q1 2024[20] - Basic earnings per share for Q1 2025 were ¥0.18, down from ¥0.26 in Q1 2024[21] Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -67,203,848.27, a significant change from CNY 127,202,516.81 in the same period last year[5] - Cash flow from operating activities for Q1 2025 was negative at -¥67.20 million, compared to positive cash flow of ¥127.20 million in Q1 2024[24] - Cash flow from investing activities for Q1 2025 was negative at -¥63.05 million, down from positive cash flow of ¥197.79 million in Q1 2024[25] - Cash and cash equivalents decreased to CNY 848,769,796.38 from CNY 941,137,361.03, reflecting a decline of 9.81%[15] - Cash and cash equivalents at the end of Q1 2025 were ¥802.47 million, a decrease from ¥1,118.39 million at the end of Q1 2024[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,584,827,117.76, a slight decrease of 0.72% from CNY 4,618,147,736.95 at the end of the previous year[6] - The total current assets as of March 31, 2025, amounted to CNY 3,650,678,618.19, a decrease of 3.13% from CNY 3,768,536,111.69 on December 31, 2024[15] - Total liabilities decreased to CNY 907,655,426.20 from CNY 968,764,195.12, a reduction of 6.31%[17] - The company's total assets as of March 31, 2025, were CNY 4,584,827,117.76, down from CNY 4,618,147,736.95[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,578[11] - The company has a share repurchase account holding 1,743,788 shares, representing 1.12% of the total share capital[12] - The company has not reported any significant changes in shareholder participation in margin trading or securities lending[13] Research and Development - R&D investment totaled CNY 26,799,907.64, which is 14.05% of revenue, an increase of 7.98 percentage points from 6.07%[6] Other Financial Metrics - The weighted average return on net assets was 0.80%, down 0.29 percentage points from 1.09%[6] - The net profit for the first quarter of 2025 is not provided in the extracted content, but the retained earnings increased to CNY 520,740,192.21 from CNY 491,860,493.37, indicating a growth of 5.06%[17] - The company reported a total equity of CNY 3,677,171,691.56, an increase from CNY 3,649,383,541.83[17] - The long-term investments increased to CNY 30,550,574.67 from CNY 30,283,435.41, showing a growth of 0.89%[16] Revenue Decline Factors - The decrease in revenue was attributed to fewer projects being accepted for commercial energy storage during the holiday season[9] Tax and Comprehensive Income - The company reported a tax expense of ¥2.88 million for Q1 2025, compared to ¥18.28 million in Q1 2024[21] - Other comprehensive income after tax for Q1 2025 was ¥5.39 million, contrasting with a loss of ¥8.03 million in Q1 2024[21]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 104,099,813.81, representing a 16.77% increase compared to CNY 89,152,510.16 in the same period last year[4] - Net profit attributable to shareholders reached CNY 17,870,494.14, a significant increase of 328.63% from CNY 4,169,185.75 year-on-year[4] - Basic and diluted earnings per share were both CNY 0.0380, reflecting a 326.97% increase from CNY 0.0089 in the same quarter last year[4] - Operating profit for Q1 2025 was CNY 17,932,298.02, significantly up from CNY 6,181,921.57 in Q1 2024, marking a 189.5% increase[18] - Total comprehensive income for Q1 2025 was CNY 17,869,070.17, compared to CNY 4,169,185.75 in Q1 2024, an increase of 328.5%[19] Cash Flow - The net cash flow from operating activities surged to CNY 34,790,900.13, marking a 455.68% increase compared to CNY 6,260,970.00 in the previous year[4] - Cash inflow from operating activities in Q1 2025 was CNY 123,477,571.15, compared to CNY 96,586,955.28 in Q1 2024, reflecting a 28.0% increase[19] - The net cash flow from investment activities was $34,944,133.15, a decrease from $129,739,268.51, indicating a decline in investment returns[20] - Cash inflow from financing activities was $379,881.15, with cash outflow totaling $899,061.79, leading to a net cash flow of -$519,180.64, down from -$2,414,583.20[20] - The net increase in cash and cash equivalents was $69,647,538.18, compared to $133,483,193.37 in the previous period, showing a decrease of approximately 47.9%[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,917,878,666.43, a 1.28% increase from CNY 1,893,682,970.18 at the end of the previous year[5] - The total current liabilities rose to RMB 117,874,688.02, compared to RMB 108,269,002.11 in the previous period, indicating an increase of about 8%[16] - The total liabilities of the company were reported at RMB 155,577,442.98, slightly up from RMB 151,946,998.96, marking a growth of around 2%[16] - The company's equity increased to RMB 1,762,301,223.45, compared to RMB 1,741,735,971.22, reflecting a growth of approximately 1.2%[16] Research and Development - Research and development expenses totaled CNY 20,692,617.34, a decrease of 10.80% from CNY 23,197,241.84, with R&D expenses accounting for 19.88% of operating revenue[5] - Research and development expenses decreased to CNY 13,417,634.91 in Q1 2025 from CNY 19,762,555.02 in Q1 2024, a reduction of 32.1%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,764, with the top ten shareholders holding a combined 73.23% of the shares[11] - The company has not reported any significant changes in shareholder relationships or actions among the top shareholders during the reporting period[13] Other Financial Metrics - The company reported non-recurring gains of CNY 5,310,185.97, primarily due to government subsidies and asset disposals[7] - The weighted average return on equity increased to 1.02%, up by 0.77 percentage points from 0.25%[4] - The company reported a foreign exchange loss of CNY 1,423.97 in Q1 2025[18] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[21]

Financial Performance - The company reported a profit distribution plan for 2024, which includes no cash dividends, no bonus shares, and no capital reserve conversion into shares[4]. - The company has not achieved profitability since its listing, indicating ongoing financial challenges[3]. - The company's operating revenue for 2024 was CNY 417.80 million, a 1.57% increase from CNY 411.36 million in 2023[22]. - The net profit attributable to shareholders for 2024 was a loss of CNY 141.20 million, compared to a loss of CNY 76.07 million in 2023, representing an 85.63% decrease year-over-year[22][24]. - The net cash flow from operating activities for 2024 was a negative CNY 37.50 million, an improvement from a negative CNY 166.22 million in 2023[22]. - The company's total assets increased by 7.04% to CNY 1.87 billion at the end of 2024, up from CNY 1.75 billion at the end of 2023[23]. - The basic earnings per share for 2024 was CNY -0.34, a decrease of 88.89% compared to CNY -0.18 in 2023[22]. - The weighted average return on net assets for 2024 was -13.42%, a decrease of 6.86 percentage points from -6.56% in 2023[22]. - The company reported a non-recurring loss of 55.70 million yuan from the disposal of non-current assets in 2023[28]. - The company received government subsidies amounting to 25.79 million yuan in the reporting period, down from 63.39 million yuan in the previous year[29]. - The company's total revenue for the reporting period was CNY 41,780.47 million, an increase of 1.57% compared to the previous year[178]. - The net profit attributable to shareholders was CNY -14,120.43 million, a decrease of 85.63% year-on-year[178]. Research and Development - Research and development expenses accounted for 25.73% of operating revenue in 2024, an increase of 5.27 percentage points from 20.46% in 2023[22][24]. - The total R&D investment for the year was approximately ¥107.5 million, representing a 27.70% increase compared to the previous year[141]. - The proportion of total R&D investment to operating income increased by 5.27 percentage points to 25.73%[141]. - The company has 27 ongoing research projects, including 7 Class 1 new drugs and 3 Class 2 new drugs, with two Class 1 innovative HIV drugs, AINOVIR and AINOMITE, approved and commercialized[61]. - The company is focusing on the development of long-acting HIV drugs, with ongoing preclinical research on lead compounds[144]. - The company has achieved significant advancements in the synthesis of key raw materials for drugs ACC007, ACC010, ACC015, and ACC017, focusing on high purity and low-cost production methods[136]. - The company has established a small molecule drug research and development platform and a human-derived protein research and development platform, focusing on project management and technical development[92]. - The company has completed the small-scale development of a single-tablet regimen for HIV patients, enhancing convenience for treatment[146]. - The company has developed multiple formulation technologies, including ACC008, which addresses solubility and stability issues of active ingredients[137]. - The company has completed enrollment for all subjects in a Phase Ib/IIa clinical study for initial HIV-infected patients, with preliminary results indicating good safety and clear efficacy of the ACC017 tablet[158]. Product Development and Innovation - The company is in the process of developing new products and technologies, although specific details were not provided in the summary[5]. - The company is actively advancing its research pipeline, with the ACC017 integrase inhibitor I phase clinical trial progressing smoothly and a patent granted[36]. - The company is developing a combination formulation centered on ACC017, which has completed small-scale and pilot studies and is advancing towards IND registration[37]. - The company is focusing on enhancing its innovation capabilities in the HIV treatment sector, aiming to meet the urgent domestic demand for HIV treatment[33]. - The company is committed to building a global industry layout based on its core areas of HIV antiviral and human protein[34]. - The company is actively pursuing clinical trials and regulatory approvals for its innovative drug candidates, positioning itself for future market expansion[136]. - The company has developed a proprietary technology for the preparation of epidermal growth factor from urine, enhancing its product portfolio in regenerative medicine[135]. - The company has established preliminary quality standards for long-acting low molecular weight heparin sodium freeze-dried powder injections, with a total investment of 15,000,000.00 RMB[150]. - The company has completed the production batch verification for ACC017 and is progressing with stability studies[144]. - The company has achieved a significant milestone with the completion of raw material drug process development for high molecular weight urokinase, with clinical research ongoing[146]. Market and Sales Performance - The total sales revenue from HIV new drugs reached CNY 149.9 million, representing a year-on-year growth of 103.73%, indicating positive progress in commercialization efforts[48]. - The revenue from the HIV new drug Aino Mite tablet reached CNY 133.54 million, a significant increase of 173.41% year-on-year[186]. - The sales volume of Urokinase crude product decreased by 24.07%, while inventory increased by 81.25%[189]. - The production volume of Aino Mite tablet increased by 185.39%, with sales volume rising by 127.07%[190]. - The company has strengthened its position in the domestic HIV innovative drug market, becoming one of the leading enterprises in this sector[123]. - The company is actively expanding its international business, with ongoing audits of overseas suppliers and the gradual development of business collaborations[51]. - The company has established a marketing strategy focused on "medical guidance, market pull, and sales implementation," enhancing brand recognition and product accessibility[165]. - The company is actively expanding its overseas market presence, particularly in Africa and Southeast Asia, to create new business growth points[166]. - The company plans to continue the commercialization of its HIV new drug and expand into overseas markets in 2025[170]. - The company is focused on promoting new products and expanding market reach following recent acquisitions and product approvals[186]. Compliance and Governance - The company has received a standard unqualified audit report from the accounting firm, ensuring the accuracy of the financial statements[4]. - There are no non-operating fund occupations by controlling shareholders or related parties, indicating financial integrity[6]. - The company has not violated decision-making procedures for external guarantees, ensuring compliance with regulations[7]. - The company has not disclosed any special arrangements in corporate governance, suggesting standard practices are in place[8]. - The company emphasizes the affordability of its innovative drugs, contributing to reduced patient burden and significant savings for national healthcare funds[74]. Risks and Challenges - The company has outlined various risk factors in its operations, which investors should consider when making investment decisions[3]. - The company faces risks related to the commercialization of its innovative drugs and potential delays in project implementation[174]. - The company has not provided specific future performance guidance or projections, reflecting a cautious outlook[5]. - The company has reported a 66.59% decrease in labor costs for urine activator crude products compared to the previous year[193]. - The company did not report any significant changes or adjustments in its business, products, or services during the reporting period[196].